Anixa Biosciences Inc (NASDAQ:ANIX)

2.18
Delayed Data
As of May 22
 +0.13 / +6.34%
Today’s Change
1.33
Today|||52-Week Range
5.45
-33.54%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$45.8M

Company Description

Anixa Biosciences, Inc. is a cancer-focused biotechnology company, which focuses on harnessing the body's immune system in the fight against cancer. It operates through the following segments: Cancer Diagnostics, Cancer Therapeutics, and Legacy Patent Licensing Activities. Cancer Diagnostic segment develops CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. Cancer Therapeutics segment offers chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.

Contact Information

Anixa Biosciences, Inc.
3150 Almaden Expressway
San Jose California 95118
P:(408) 708-9808
Investor Relations:
1408

Employees

Shareholders

Mutual fund holders4.00%
Other institutional2.61%
Individual stakeholders13.43%

Top Executives

There are no executives to display.